Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZentivaBSE:SCD 10 EV-to-OCF is 49.91 as of Sep. 04, 2026, which is 48% above its 10-year median of 33.74. GuruFocus rates BSE:SCD with a GF Score™ of 10/100.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Zentiva's Enterprise Value is lei3,147 Mil.
Zentiva's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 was lei63 Mil. Therefore, Zentiva's EV-to-OCF for today is 49.91.
The historical rank and industry rank for Zentiva's EV-to-OCF or its related term are showing as below:
BSE:SCD'
s EV-to-OCF Range Over the Past 10 Years
Min: -1753.85 Med: 33.74 Max: 1993.67
Current: 49.91
During the past 13 years, the highest EV-to-OCF of Zentiva was 1993.67. The lowest was -1753.85. And the median was 33.74.
BSE:SCD's EV-to-OCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 10.355
vs BSE:SCD: 49.91
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-04), Zentiva's stock price is lei4.52.
Zentiva's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was lei0.329. Therefore, Zentiva's PE Ratio (TTM) for today is 13.74.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zentiva's share price for today is lei4.52.
Zentiva's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.329.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zentiva EV-to-OCF Related Terms
Zentiva EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Zentiva's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zentiva's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zentiva EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zentiva's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Zentiva's EV-to-OCF falls into.
Zentiva's current Enterprise Value is lei3,147 Mil.
Zentiva's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was lei63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zentiva (BSE:SCD) has a EV-to-OCF of 49.91 as of Sep. 04, 2026. This is 48% above median its historical median of 33.74.
Is Zentiva's EV-to-OCF too high?
Zentiva's current EV-to-OCF of 49.91 is 48% above median its 10-year median of 33.74. The Drug Manufacturers industry median EV-to-OCF is 10.36. Zentiva's value of 49.91 is 382% above this industry median. Overall, Zentiva has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Zentiva's EV-to-OCF compare to ZTS and VTRS?
Zentiva's EV-to-OCF of 49.91 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-OCF is 10.36. Zentiva's value of 49.91 is 382% above this benchmark. While the company's 10-year median is 33.74 vs. the industry median of 10.36, Zentiva has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.36, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zentiva's current EV-to-OCF of 49.91 is 382% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zentiva's current EV-to-OCF is 49.91, which is 48% above median its own 10-year median of 33.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentiva stock overvalued right now?
Zentiva (BSE:SCD) has a current EV-to-OCF of 49.91. The current EV-to-OCF is 49.91, which is 48% above median its 10-year median of 33.74 and 382% above the Drug Manufacturers industry median of 10.36. Zentiva's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Zentiva (BSE:SCD), the current EV-to-OCF is 49.91 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zentiva SA is a Romania-based producer of medicines on the local market. The product portfolio of Zentiva SA includes more than 126 products for human use, such as solids (tablets, capsules, and pellets), generic products, and injectable solutions. The company provides products for therapeutic areas such as Cardiovascular diseases, Anti-inflammatory and pain-relieving medications, urologists, Blood diseases, Gastrointestinal and metabolic disorders, Central nervous system, Medicines against infections, and Diseases of the respiratory system.
10GF Score
Get the complete analysis for BSE:SCD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:SCD has been successfully added to your 
